The removal of urokinase from the market has created a dilemma for interventionists and vascular surgeons treating patients with acute limb threatening ischemia due to arterial thrombosis or embolization. Reteplase is a newer, fibrin-specific thrombolytic agent with properties that make it an attractive alternative to urokinase. We report two cases of successful treatment of acute, limb threatening ischemia with intra-arterial Reteplase therapy.
|Original language||English (US)|
|Number of pages||6|
|Journal||Journal of Invasive Cardiology|
|State||Published - 1999|
- Peripheral vascular disease
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine